Views:6 Author:Site Editor Publish Time: 2020-01-09 Origin:Site
On the afternoon of January 9, 2020, Research & Development Head of Hitachi Group, Mr. Yoshiyuki and his team visited Xi’an Tianlong. Hitachi is a Japan-based Global Fortune 500 MNC, with its comprehensive business scope involving healthcare, energy, transportation, information systems, and so on. With the trends of global economic integration and the further opening of China's market, Hitachi Group hopes to develop more extensive and in-depth cooperation with Chinese healthcare enterprises.
In the afternoon, accompanied by the assistant to Tianlong’s General Manager, Mr. Liang Jiaming, Mr. Yoshiyuki visited the reagent production workshop in the Yuanzheng Expedition Industrial Park, and the site manager Chen Aiqin introduced the three areas of reagent production, daily production capacity of reagents and the management systems. Mr. Yoshiyuki and team highly recognized the standardized production workshop and the daily production capacity of Tianlong, and also praised the '5S' management system that we learned from Japanese management practices. Then, Mr. Yoshiyuki visited the Tianlong Intelligent Medical Device and Equipment Production Base, which covers an area of 30 acres with a planned total investment of 200 million RMB mainly used for the R & D and production of intelligent medical devices and equipment. The base iis expected to be put into use by the end of 2020.
After returning to the Tianlong headquarters, accompanied by General Manager Mr. Li Ming and team, Mr. Yoshiyuki visited Tianlong product showroom, instrument production workshop, R&D center and so on. Mr. Li Yanfeng, Director of overseas business, gave a detailed introduction of Tianlong’s history and product pipelines. Li Zheng, Director of R&D center, briefly introduced the new projects under researching, among which, the digital PCR project is a National Key Research and Development Project. Mr. Yoshiyuki expressed great interests in this project and expressed his confidence in the future market.
After the tour, Mr. Yoshiyuki had a seminar with Tianlong leaders. At this meeting, Director Li Yanfeng gave a detailed introduction of Tianlong, and the prospects of the cooperation between the two. The Acting Minister Miyake expressed the cooperation intention of Hitachi Group. Ms. Sun Yao, Assistant Director of Tianlong R&D Center, introduced the initial results of the cooperation project. At last, Tianlong leaders had an in-depth discussion with Mr. Yoshiyuki and team about the cooperation projects and details. 'The development of molecular diagnostic industry in China has been very fast, and Tianlong is looking forward to the close cooperation in R&D with the advantages of Hitachi Group in health management, diagnostics and medical technologies, so as to develop more suitable products for the market and clinical uses', said Mr. Li. 'Tianlong has a complete chain of products and enjoys a great share of the local genetic testing and molecular diagnostics market. We also want to take advantage of Tianlong's existing resources to quickly enter the Chinese market. In addition, we also look forward to in-depth technical cooperation with Tianlong to develop more suitable medical diagnostic products for the Chinese market.” said Mr. Yoshiyuki , after the meeting.
Although the meeting was brief yet very fruitful. The two sides reached a preliminary cooperation intention in business channels, product R&D and manufacturing, etc. Tianlong will continue to strengthen technology innovation, to create a more complete product chain. We look forward to further cooperation with Hitachi.